Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?

被引:6
|
作者
Zanella, Isabella [1 ,2 ]
Degli Antoni, Melania [3 ,4 ]
Marchese, Valentina [3 ,4 ]
Castelli, Francesco [3 ,4 ]
Quiros-Roldan, Eugenia [3 ,4 ]
机构
[1] Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy
[2] ASST Spedali Civili Brescia, Diagnost Dept, Cytogenet & Mol Genet Sect, Clin Chem Lab, I-25123 Brescia, Italy
[3] Univ Brescia, Dept Infect & Trop Dis, I-25123 Brescia, Italy
[4] ASST Spedali Civili Brescia, I-25123 Brescia, Italy
关键词
Antibody-dependent enhancement; Neutralizing antibodies; SARS-CoV-2; Therapies; Vaccines; DEPENDENT ENHANCEMENT; SARS-COV; VIRUS; IMMUNOPATHOLOGY; IMMUNIZATION; PROTEIN;
D O I
10.1016/j.intimp.2022.108943
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody-dependent enhancement (ADE) is a complex phenomenon mediated by antibodies, frequently preexisting non-neutralizing or sub-neutralizing antibodies. In the course of infectious diseases, ADE may be responsible for worsening the clinical course of the disease by increasing the virulence of pathogens (ADE of infection) or enhancing disease severity (ADE of disease). Here we reviewed the mechanisms thought to be behind the ADE phenomenon and its potential relationship with COVID-19 severity. Since the early COVID-19 epidemics, ADE has been mentioned as a possible mechanism involved in severe COVID-19 disease and, later, as a potential risk in the case of infection after vaccination. However, current data do not support its role in disease severity, both after infection and reinfection.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Neutralizing antibodies targeting SARS-CoV-2 spike protein
    Shi Xiaojie
    Li Yu
    Yan Lei
    Yang Guang
    Qiang Min
    STEM CELL RESEARCH, 2021, 50
  • [42] Duration of SARS-CoV-2 Serum-Neutralizing Antibodies Against SARS-CoV-2 Dependent on the Individual
    Li, Jin
    Zou, Li
    Li, Shaojie
    Zou, Ruogu
    Fang, Zhixiong
    Zhang, Pingan
    Li, Huijun
    Wang, Shanshan
    Ke, Dong
    Gao, Peng
    Jin, Cuicui
    Fang, Cong
    Zhou, Ji
    He, Ellen
    Skog, Sven
    VIRAL IMMUNOLOGY, 2023, 36 (03) : 153 - 162
  • [43] Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
    Imbrechts, Maya
    Maes, Wim
    Ampofo, Louanne
    Van den Berghe, Nathalie
    Calcoen, Bas
    Van Looveren, Dominique
    Kerstens, Winnie
    Rasulova, Madina
    Vercruysse, Thomas
    Noppen, Sam
    Abdelnabi, Rana
    Foo, Caroline
    Hollevoet, Kevin
    Maes, Piet
    Zhang, Xin
    Jochmans, Dirk
    Ven, Karen
    Lammertyn, Jeroen
    Vanhoorelbeke, Karen
    Callewaert, Nico
    De Munter, Paul
    Schols, Dominique
    Thibaut, Hendrik Jan
    Neyts, Johan
    Declerck, Paul
    Geukens, Nick
    ISCIENCE, 2022, 25 (08)
  • [44] Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion
    Li, Chia-Jung
    Chao, Tai-Ling
    Chang, Ting-Yu
    Hsiao, Chia-Chun
    Lu, De-Chao
    Chiang, Yi-Wei
    Lai, Guan-Chun
    Tsai, Ya-Min
    Fang, Jun-Tung
    Ieong, Siman
    Wang, Jann-Tay
    Chang, Sui-Yuan
    Chang, Shih-Chung
    MICROBIOLOGY SPECTRUM, 2022, 10 (02):
  • [45] Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
    Tan, Yun
    Liu, Feng
    Xu, Xiaoguang
    Ling, Yun
    Huang, Weijin
    Zhu, Zhaoqin
    Guo, Mingquan
    Lin, Yixiao
    Fu, Ziyu
    Liang, Dongguo
    Zhang, Tengfei
    Fan, Jian
    Xu, Miao
    Lu, Hongzhou
    Chen, Saijuan
    FRONTIERS OF MEDICINE, 2020, 14 (06) : 746 - 751
  • [46] A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
    Cobb, Ronald R.
    Nkolola, Joseph
    Gilchuk, Pavlo
    Chandrashekar, Abishek
    Yu, Jingyou
    House, Robert, V
    Earnhart, Christopher G.
    Dorsey, Nicole M.
    Hopkins, Svetlana A.
    Snow, Doris M.
    Chen, Rita E.
    VanBlargan, Laura A.
    Hechenblaickner, Manuel
    Hoppe, Brian
    Collins, Laura
    Tomic, Milan T.
    Nonet, Genevieve H.
    Hackett, Kyal
    Slaughter, James C.
    Lewis, Mark G.
    Andersen, Hanne
    Cook, Anthony
    Diamond, Michael S.
    Carnahan, Robert H.
    Barouch, Dan H.
    Crowe, James E., Jr.
    MED, 2022, 3 (03): : 188 - +
  • [47] Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
    Yun Tan
    Feng Liu
    Xiaoguang Xu
    Yun Ling
    Weijin Huang
    Zhaoqin Zhu
    Mingquan Guo
    Yixiao Lin
    Ziyu Fu
    Dongguo Liang
    Tengfei Zhang
    Jian Fan
    Miao Xu
    Hongzhou Lu
    Saijuan Chen
    Frontiers of Medicine, 2020, 14 : 746 - 751
  • [48] Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies
    Zhou, Dongyan
    Chan, Jasper Fuk-Woo
    Zhou, Biao
    Zhou, Runhong
    Li, Shuang
    Shan, Sisi
    Liu, Li
    Zhang, Anna Jinxia
    Chen, Serena J.
    Chan, Chris Chung-Sing
    Xu, Haoran
    Poon, Vincent Kwok-Man
    Yuan, Shuofeng
    Li, Cun
    Chik, Kenn Ka-Heng
    Chan, Chris Chun-Yiu
    Cao, Jianli
    Chan, Chun-Yin
    Kwan, Ka-Yi
    Du, Zhenglong
    Lau, Thomas Tsz-Kan
    Zhang, Qi
    Zhou, Jie
    To, Kelvin Kai-Wang
    Zhang, Linqi
    Ho, David D.
    Yuen, Kwok-Yung
    Chen, Zhiwei
    CELL HOST & MICROBE, 2021, 29 (04) : 551 - +
  • [49] Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
    Wang, Meiyu
    Zhang, Li
    Li, Qianqian
    Wang, Bo
    Liang, Ziteng
    Sun, Yeqing
    Nie, Jianhui
    Wu, Jiajing
    Su, Xiaodong
    Qu, Xiaowang
    Li, Yuhua
    Wang, Youchun
    Huang, Weijin
    EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 18 - 29
  • [50] Correlation between the atellica SARS-COV-2 IGG assay results and the presence of SARS-COV-2 neutralizing antibodies
    Bedini, J.
    Filella, X.
    Hidalgo, S.
    Gonzalez-Escribano, C.
    CLINICA CHIMICA ACTA, 2022, 530 : S320 - S320